| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916013 | Nuclear Medicine and Biology | 2014 | 7 Pages |
Abstract
This is the first report to demonstrate the impact of the multi-targeted Aurora B kinase inhibitor, TAK-901 on tumor FLT uptake. The findings provide a strong rationale for the evaluation of FLT-PET as an early biomarker of tumor response in the early phase clinical development of this compound.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carleen Cullinane, Kelly L. Waldeck, David Binns, Ekaterina Bogatyreva, Daniel P. Bradley, Ron de Jong, Grant A. McArthur, Rodney J. Hicks,